All
Incorporating Immunotherapy Into Hodgkin Lymphoma Treatment Strategies
Stephen M. Ansell, MD, PhD, discusses how immunotherapy is being integrated into treatment for patients with advanced stage Hodgkin lymphoma.
FDA Approves Asciminib in Newly Diagnosed Ph+ CML in Chronic Phase
Asciminib has gained accelerated approval from the FDA for the treatment of patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Exploring the Benefits of Nab-Sirolimus in Advanced PEComa Treatment
In an interview with Targeted Oncology, Jacob Stein, MD, MPH, discussed nab-sirolimus and its impact on patients with advanced PEComa.
Key Findings From the CARTITUDE-4 Trial of Cilta-Cel in Multiple Myeloma
Binod Dhakal, MD, MS, discusses the safety and efficacy findings from the CARTITUDE-4 trial.
Overview of the CARTITUDE-4 Trial: Cilta-Cel in Multiple Myeloma
Binod Dhakal, MD, MS, provides an overview of the CARTITUDE-4 trial, including its methods, design, and inclusion criteria.
Genetic Clues to Early-Onset TNBC in Black Women
Holly Pederson, MD, and Elisha Hughes, MD, discussed the use of a polygenic risk score to identify why Black women incur higher rates of triple-negative breast cancer at younger ages.
FDA Expands Approval for Jylamvo Oral Methotrexate Solution in ALL
The indication for Jylamvo now includes pediatric patients with acute lymphoblastic leukemia.
AI Outperforms Standard HRD Tests for Breast, Ovarian Cancers
DeepHRD predicted homologous recombination deficiency with greater accuracy than FDA-approved standard molecular tests.
Continued Investigation of T-DXd Shows Promise in Breast Cancer
Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.
Investigational FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer
TYRA-300 showed promising safety and preliminary antitumor activity in FGFR3-altered metastatic urothelial cancer, with a 54.5% partial response rate and 100% disease control in the SURF301 trial.
FDA Fast Tracks HC-7366 in Relapsed/Refractory Acute Myeloid Leukemia
The FDA granted fast track status to HC-7366 for relapsed/refractory AML treatment.
Comparing Emerging Classes of Endocrine Therapies in Breast Cancer
Erika Hamilton, MD, discusses the different classes of endocrine therapies and how they compare to one another.
Lenvatinib/Pembrolizumab/TACE Regimen Improves PFS in Intermediate-Stage HCC
Josep M. Llovet, MD, PhD, discussed the updated data from the LEAP-012 trial in intermediate-stage hepatocellular carcinoma.
Exploring the Perioperative Treatment Setting in Lung Cancer
An expert addressed the emerging role of immune checkpoint inhibitors in the perioperative space based on findings from the CheckMate 816, IMpower010, PEARLS, and ADAURA trials.
The Targeted Pulse: Unpack The Latest FDA Approvals and Updates, Including A New Dosage For HER2 Cancers
This week’s recap highlights several significant FDA developments. We also cover ongoing successes of pembrolizumab with chemotherapy in NSCLC.
Behind the ECOG-ACRIN E1910 Trial: Blinatumomab in B-ALL
Mark R. Litzow, MD, discusses the methods and design used in the ECOG-ACRIN E1910 trial.
Analysis Shows Perioperative Pembrolizumab Efficacy in NSCLC
Neoadjuvant pembrolizumab with chemotherapy led to greater pathologic regression based on percent residual volume tumor vs placebo plus chemotherapy in patients with early-stage non–small cell lung cancer.
BOVen Regimen Appears Effective in High-Risk MCL
Zanubrutinib, obinutuzumab, and venetoclax delivered promising response and survival data for the treatment of patients with mantle cell lymphoma harboring a TP53 mutation.
Liquid Biopsies Enhance PSMA-Directed Therapies in GU Cancers
Jacob E. Berchuck, MD, discusses the potential of liquid biopsies to enhance clinical decision-making regarding PSMA-directed therapies.
Upcoming Endocrine Therapy Developments Excite in Breast Cancer
Erika Hamilton, MD, discusses how novel endocrine therapies improve treatment for metastatic breast cancer.
Emerging Endocrine Therapies in Breast Cancer Treatment
Erika Hamilton, MD, discusses some of the most promising endocrine therapies in breast cancer.
Developing a Malignant Hematology and Bone Marrow Transplant APP Fellowship
Janelle Vicens, DNP, APRN, FNP-BC, and Sandra Sepulveda, AGPNP-BC, MSN, BMTCN, discussed what went into developing this Malignant Hematology and Bone Marrow Transplant APP Fellowship.
Nab-Sirolimus and Its Role in PEComa Treatment
Jacob Stein, MD, MPH, discusses how nab-sirolimus improves outcomes for patients with advanced perivascular epithelioid cell tumors compared with other treatments or no treatment options.
POLESTAR Results Show PFS Benefit of Aumolertinib in NSCLC
Aumolertinib improved progression-free survival vs placebo in patients with unresectable stage III non–small cell lung cancer, according to data from an interim analysis of the phase 3 POLESTAR trial.
Kalman Unveils Insights on Thyroid Cancer Prognosis and Treatments
Noah S. Kalman, MD, MBA, discusses the most common types of thyroid cancer and their respective prognoses.
Gupta Explores Sacituzumab Govitecan in Advanced Breast Cancer Treatment
Following discussions on ado-trastuzumab emtansine and fam-trastuzumab deruxtecan-nxki, Tanya Gupta, MD, discusses sacituzumab govitecan and its approval from the FDA in the breast cancer space.
The Present and Future of Endocrine Therapy in Breast Cancer
In an interview with Targeted Oncology, Erika Hamilton, MD, discussed emerging endocrine therapies that are advancing breast cancer treatment.
FDA Grants Priority Review for TLX101-CDx PET Imaging Agent in Glioma
The FDA accepted the new drug application for TLX101-CDx and granted priority review to the agent in glioma.
Breakthroughs and Challenges in BCL-2 Inhibitor Therapy for CLL Treatment
John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.
Ivonescimab Reduces Risk of Progression Over Pembrolizumab in PD-L1+ Advanced NSCLC
Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer.